Preoperative screening for LVAD an TAH implantation

Slides:



Advertisements
Similar presentations
Off pump CABG has been performed for the first time 40 years ago. Although conventional CABG is considered both safe and effective, the use of CBP.
Advertisements

Assisted Circulation MEDICAL MEDICAL  Drugs  EECP MECHANICAL  IABP ( Introaortic balloon pump)  VAD (Ventricular assist device)
Hemolysis in Patients Supported with Durable, Long-Term Left Ventricular Assist Device Therapy Jason N. Katz, MD,MHS; Brian C. Jensen, MD; Patricia P.
HEART TRANSPLANTATION Pediatric Recipients ISHLT 2012 J Heart Lung Transplant Oct; 31(10):
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Mechanical Circulatory Support for Advanced Heart Failure Speakers: Lynne A Benish, ACNP-BC Mechanical Assist Device Nurse Practitioner, Cardiac Surgery.
Advances In LVAD Patient Management
Introduction to Ventricular Assist Device (VAD)
Joseph G. Rogers, MD Professor of Medicine Duke University
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH.
Biventricular Failure – Total Artificial Heart Francisco A. Arabía, MD Director, CHSI Center for Surgical Device Management Cedars-Sinai Heart Institute.
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
Contemporary Outcomes With the HeartMate II® LVAS
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
HEART TRANSPLANTATION Pediatric Recipients JHLT Oct; 32(10):
HeartWare HVAD: Risk Factors for Adverse Outcomes Mark S. Slaughter, MD Professor and Chair Department Cardiovascular and Thoracic Surgery University of.
RDB Jaquiss Duke University
Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.
How I would do my anterior VSD Closure
Optimal Therapies for End-Stage Thoracic Organ Failure: The Critical Role of the Surgeon and the Use of ECMO, MCS and Transplantation Decision Making:
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical.
When and How to Replace an LVAD
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children’s.
Clinical Review AbioCor® Implantable Replacement Heart H Julie Swain M.D. Cardiovascular Surgeon Ileana Piña M.D. Heart Failure Cardiologist DRAFT.
Mechanical Circulatory Support Cardiogenic Shock Post AMI
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
“Rise of the Machines” Todd D. Edwards MD FACC FACP FASNC.
MCSRN Mechanical Circulatory Support Research Network
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
S. Bouchez, MD°, S. Jacobs, MD°, I Herck, MD #, F. De Somer, PhD*, Y. Van Belleghem, MD*. ° Department of Anaesthesiology, University of Ghent, Belgium.
P. Leprince, CT Surgery Institut of cardiology Pitié-Salpétrière Group Paris, France The Total Artificial Heart Cardiowest: Indications and Results.
Concomitant Aortic Valve Repair in Patients Undergoing Continuous-flow Left Ventricular Assist Device Placement: A 10-year Experience and Clinical Implications.
Assistances Circulatoires: actualités
Extracorporeal Membrane Oxygenation for Bridge to Decision and to Recovery Shigeki Tabata, Hitoshi Hirose, Nicholas C. Cavarocchi, James T. Diehl, Hiroyuki.
Michael S Kiernan, MD, SM Assistant Professor, Tufts University Medical Director Ventricular Assist Device Program, Tufts Medical Center.
The SynCardia CardioWestTM Total Artificial Heart
Percutaneous RVAD support following LVAD implant
The Aortic Valve Patient Learning Objectives
Total Artificial Heart (TAH): Survival Outcomes, Risk Factors,
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
University of Chicago Medicine
Ventricular function recovery on LVAD For idiopathic or ischemic CM
Assist Devices for the Treatment of Cardiogenic Shock
Role of ECMO in Acute Cardiogenic Shock
Mechanical circulatory support
Pre-operative mortality risk assessment in patients with continuous-flow left ventricular assist devices: Application of the HeartMate II risk score 
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Monaldi Hospital -Azienda Ospedaliera dei Colli - Naples (IT)
ECMO and advanced intensive care Euro-Elso 2013
What Patients Should Know About the New Adult Heart Allocation System
The Use of Impella for CGS Patients Does It Save Lives?
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) – Long Term Outcomes.
What Patients Should Know About the New Adult Heart Allocation System
Mechanical Circulatory Support Devices HOSEIN PASANDI.
The Mitral Valve Patient Learning Objectives
Effects on pre- and posttransplant pulmonary hemodynamics in patients with continuous-flow left ventricular assist devices  Ranjit John, MD, Kenneth Liao,
Juan J. Russo et al. JACC 2019;73:
Total ventricular assist for long-term treatment of heart failure
Adverse events in contemporary continuous-flow left ventricular assist devices: A multi- institutional comparison shows significant differences  John M.
Abdul Rahman Dakkak, MD, Angelo M. Dell'Aquila, MD, Juergen R
Ranjit John, MD, Yoshifumi Naka, MD, Soon J
Jerry D. Estep et al. JCHF 2013;1:
Procedural Characteristics
Is severe right ventricular failure in left ventricular assist device recipients a risk factor for unsuccessful bridging to transplant and post-transplant.
Daisuke Yoshioka, MD, Hiroo Takayama, MD, Arthur R. Garan, MD, Veli K
A. Procopi, N. Procopi, JP Collet, O. Barthelemy, P. Leprince, R
The Journal of Thoracic and Cardiovascular Surgery
Presentation transcript:

Preoperative screening for LVAD an TAH implantation P. Leprince Institut de cardiologie Chirurgie Cardiovasculaire Groupe Hospitalier Pitié-Salpétrière Paris, France Pascal.leprince@aphp.fr

Disclosure St Jude (Abott): Heartmate II Medtronic: HVAD, ECMO Jarvik 2000 Syncardia

Pre operative assessment Assess Illness severity Patient selection Optimize the sickest patients Define risk factor for surgery Right ventricle assessment Other organic and functional considerations Select appropriate device

Illness assessment for operative risk

Low: < 1.58 Mid: 1.58-2,58 High: > 1.58

3 centers 101 patients Intermacs 1 (28) Intermacs 2-3 (49) AJ Boyle et al. JHLT 2011, 30: 402

Intermacs 2016 report

BTB: HVAD 2012-2014 La Pitié 38 patients, 33 males 51± 12.5 y 12(31%) bridge to LVAD with peripheral ECMO 29 (76%) implanted on ECMO (vs CPB +valvular surgery) 7 (18%) peripheral ECMO + HVAD 17 (45%) percutaneous ECMO RVAD + HVAD  63 % RVAD support 71% hospital discharge

No ECMO ECMO pre N=26 N=12 No support ECMO Pc RVAD No support ECMO 31% N=5 19% N=13 50% N=6 50% N=2 16% N=4 33% 87% 60% 54% 83% 100% 75%

Infection screening and control

Right ventricular function Echocardiography TAPSE S wave Strain Septal function LV/RV ratio

In case of RV dysfunction Patient optimisation: inotropes, diuresis, CVVHD Biventricular or TAH support LVAD with temporary RVAD

Percutaneous temporary RVAD

Temporary percutaneous ECMO RVAD

Percutaneous temporary ECMO RVAD   N = 27 RVAD Timing (j) 2,1 ± 5,4 Duration (j) 12,9 ± 7,6 Devenir Death under RVAD 10 (37,0%) Weaning from RVAD 17 (63,0%) Transplantation 3 (11,1%) 6 months death 14 (51,8%) 50% 67% John n=12 14 d 21% 53% Bad-O n=45 21 j 64% Dang n=14 13 d

Other considerations Pulmonary function Neurologic function +++Carotide art. assessment Valvular disease +++ aortic valve Arrhytmias Psychologic and psychiatric conditions Social conditions

Which device for which patient? Center experience with multiple devices RV Function? Heart transplant candidate or DT patient? Body size: output vs space Surgical technic: sternotomy vs thoracotomy redo patient CPB vs ECMO vs off pump? Hemorrhagic risk

Requirement for biventricular support Syncardia Carmat Double LVAD LVAD + temporary RVAD TAH with BiHVAD La Pitié

Which device for which patient? Center experience with multiple devices RV Function? Heart transplant candidate or DT patient? Body size: output vs space Surgical technic: sternotomy vs thoracotomy redo patient CPB vs ECMO vs off pump? Hemorrhagic risk

Which device for which patient? Center experience with multiple devices RV Function? Heart transplant candidate or DT patient? Body size: output vs space Surgical technic: sternotomy vs thoracotomy redo patient CPB vs ECMO vs off pump? Hemorrhagic risk

Biventricular Destination BTT HMIII LVAD

Спасибо Большое